Multiple studies have highlighted the significance of plasma-based biomarkers, particularly Aβ ratios, p-tau, t-tau, NfL, and GFAP, in advancing the diagnostic and prognostic framework for AD and potentially other types of dementia. The gene discussed is NEFL; the disease is Alzheimer disease.